Soaring Demand Set to Propel Intussusception Market to $5.52 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

What Is the Expected CAGR for the Intussusception Market Through 2025?
The market size of intussusception has witnessed a significant increase in recent times. It is forecasted to expand from $4.45 billion in 2024 to $4.69 billion in 2025, with a compound annual growth rate (CAGR) of 5.3%. The growth experienced during the historic period can mainly be associated with enhancements in diagnostic capabilities, heightened consciousness and education, the expansion of global healthcare systems, and investments in research and development, as well as collaboration within healthcare organizations.

What's the Projected Size of the Global Intussusception Market by 2029?
It is projected that the market size for intussusception will witness a steady swell in the upcoming few years, escalating to $5.52 billion by 2029 at a CAGR of 4.1%. The market expansion during this forecast period could be linked to various factors including the ongoing enhancement of medical education, initiation of pediatric vaccination programs, worldwide initiatives towards improving pediatric healthcare, emphasis on postoperative care, and an increasing need for research in pediatric gastroenterology, combined with the rising prominence of telemedicine and access to remote healthcare services. Key trends predicted for this forecast period encompasses progressions in diagnostic imaging, adoption of minimally invasive treatment methods, the inception of interventions particularly aimed at pediatrics, research focusing on etiology and risk factors, comprehensive global disease studies, the execution of vaccination schemes, and the application of telemedicine for diagnosis and consulting purposes.

View the full report here:
https://www.thebusinessresearchcompany.com/report/intussusception-global-market-report

Top Growth Drivers in the Intussusception Industry: What's Accelerating the Market?
The surge in intestinal disorders is predicted to fuel the expansion of the intussusception market in the future. Intestinal disorders are health concerns or medical conditions that disrupt the regular operation of the intestines, which play a significant role in the digestive system by absorbing essential nutrients and expelling waste from the body. The growing prevalence of such disorders, including inflammatory bowel disease and gastrointestinal cancers, can lead to earlier detection, superior treatment alternatives, and increased support for those suffering from intussusception, thus endorsing their health and welfare. For example, the American Cancer Society (ACS) reported in January 2023 that gastrointestinal cancers in the United States rose by 3.18% to 348,840 from 338,090 in 2021. Consequently, the increased occurrence of intestinal disorders will spur on the intussusception market's growth. The intussusception market is also witnessing a surge due to elevated healthcare spending. Healthcare expenditure encompasses the sum of financial resources invested into the health sector within a specific area, country, or establishment. It involves allocating finances to cater to medical needs, and the rise in conditions like intussusception call for increased spending by necessitating medical services, diagnostic tests, and possible surgical procedures, affecting total healthcare costs. According to the Canadian Institute for Health Information, total health expenditure in Canada in 2023 is estimated at $344 billion, which amounts to $8,740 per individual. This denotes a 2.8% rise from the last year, which only documented a 1.5% increment in health spending in 2022, indicating a significant recovery in healthcare investment. Therefore, boosted healthcare spending is propelling the expansion of the intussusception market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13466&type=smp

What Trends Will Shape the Intussusception Market Through 2029 and Beyond?
Leading businesses in the intestinal pseudo-obstruction treatment market are focusing on innovating novel drug therapies such as NHE3 inhibitor treatment therapy, with the aim of providing their clients with trustworthy services. NHE3 inhibitor treatment therapy functions by suppressing the Sodium-Proton-Exchanger subtype 3 (NHE3) present in the gut. Notably, in April 2022, Ardelyx Inc., a biopharmaceutical firm based in the United States, launched IBSRELA. This NHE3 inhibitor treatment aims to alleviate irritable bowel syndrome with constipation (IBS-C) in adults and potentially enhance gastrointestinal motility. The function of IBSRELA treatment therapy revolves around inhibiting the action of the Sodium-Hydrogen Exchanger 3 (NHE3) protein. The approval of IBSRELA was based on two Phase 3 tests carried on over 1,200 IBS-C patients. The treatment demonstrated significant improvement in abdominal pain and bowel movement patterns and achieved the primary endpoint. This improvement was seen from the first week itself and lasted up to 26 weeks in the long-term trial.

What Are the Main Segments in the Intussusception Market?
The intussusception market covered in this report is segmented -

1) By Type: Idiopathic Intussusception, Secondary Intussusception
2) By Treatment: Enema Reduction, Surgery, Other Treatment
3) By Diagnosis: Barium Enema, Ultrasound, X-Ray, Computerized Tomography (CT)
4) By End-User: Hospitals, Clinics, Other End-User

Subsegments:
1) By Idiopathic Intussusception: Childhood Idiopathic Intussusception, Adult Idiopathic Intussusception
2) By Secondary Intussusception: Neoplastic Intussusception, Infectious Intussusception, Inflammatory Intussusception, Post-Surgical Intussusception

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13466&type=smp

Which Top Companies are Driving Growth in the Intussusception Market?
Major companies operating in the intussusception market report are Pfizer Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Abbott Laboratories, Sanofi S.A., GlaxoSmithKline PLC, Stryker Corporation, Boston Scientific Corporation, Biogen Inc., Olympus Corporation, GE HealthCare Technologies Inc., Steris PLC, Cook Medical LLC, Shimadzu Corporation, Carestream Health, CONMED Corporation, Janssen Pharmaceuticals Inc., EndoChoice Holdings Inc., Fujifilm Healthcare Solutions, Basilea Pharmaceutica Ltd., Richard Wolf GmbH, Karl Storz SE And Co. KG, Eizoflex Co. Ltd., Arena Pharmaceuticals Inc.

Which Regions Will Dominate the Intussusception Market Through 2029?
North America was the largest region in the intussusception market in 2024. The regions covered in the intussusception market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13466

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.